<- Go Home
The Medicines Company
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was incorporated in 1996 and is headquartered in Parsippany, New Jersey. As of January 3, 2020, The Medicines Company operates as a subsidiary of Novartis AG.
Market Cap
$6.8B
Volume
1.5M
Cash and Equivalents
$265.9M
EBITDA
-$176.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$697.0K
Profit Margin
N/A
52 Week High
$84.98
52 Week Low
$17.81
Dividend
N/A
Price / Book Value
-113.17
Price / Earnings
-26.85
Price / Tangible Book Value
-25.91
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$178.9M
Return on Equity
553.30%
Return on Assets
-13.71
Cash and Short Term Investments
$268.4M
Debt
$865.0M
Equity
-$59.5M
Revenue
N/A
Unlevered FCF
-$117.2M
Sector
Biotechnology
Category
N/A